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Interleukin-23 (IL-23) is known to play a crucial role in the development and maintenance of T helper 17
cells. It has been previously demonstrated that IL-17 is involved in experimental Lyme arthritis, caused by
Borrelia burgdorferi bacteria. However, the precise role of the IL-23 receptor (IL-23R) for the B. burgdorferi-
induced IL-17 responses or human Lyme disease has not yet been elucidated. IL-23R single nucleotide
polymorphism (SNP) rs11209026 was genotyped using the TaqMan assay. Functional studies were performed
using peripheral blood mononuclear cells, and cytokines were measured using enzyme-linked immunosorbent
assay (ELISA). Dose-dependent production of IL-23 and IL-17 by B. burgdorferi could be observed. Interest-
ingly, when IL-23 bioactivity was inhibited by a specific antibody against IL-23p19, IL-17 production was
significantly downregulated. In contrast, production of gamma interferon (IFN-) was not affected after the
blockade of IL-23 activity. Moreover, individuals bearing a single nucleotide polymorphism in the IL-23R gene
(Arg381Gln) produced significantly less IL-17 after B. burgdorferi stimulation compared with that of the
individuals bearing the wild type. Despite lower IL-17 production, the IL-23R gene polymorphism did not
influence the development of chronic Lyme disease in a cohort of patients with Lyme disease. This study
demonstrates that IL-23R signaling is needed for B. burgdorferi-induced IL-17 production in vitro and that an
IL-23R gene SNP leads to impaired IL-17 production. However, the IL-23R gene polymorphism is not crucial
for the pathogenesis of chronic Lyme.
Lyme disease begins in most individuals with a localized skin
infection (erythema migrans [EM]) caused by the pathogenic
Borrelia burgdorferi spirochetes after transmission by an in-
fected tick. When dissemination of B. burgdorferi occurs, the
second stage of Lyme disease is established, which eventually
leads to persistent Lyme disease. Several chronic inflammatory
processes can be distinguished in Lyme patients, including
inflammation of the central nervous system (neuroborreliosis),
inflamed skin (acrodermatitis chronica atrophicans [ACA]), or
joint inflammation (Lyme arthritis) (30). The precise immuno-
logical mechanisms leading to the development of persistent
Lyme disease are still unclear. While detection of live B. burg-
dorferi microorganisms in patients is difficult, chronic Lyme
disease displays clinical similarities with autoimmune disorders
such as rheumatoid arthritis (RA) and multiple sclerosis (MS),
in which T cells are known to play important roles. Pathogenic
Th17 cells (CD4 T cells) play a prominent role in the patho-
genesis of these diseases (8, 21, 23).
Of interest, proinflammatory cytokine interleukin-1 (IL-
1) is essential for the development of Th17 responses, and B.
burgdorferi is a potent inducer of IL-1 (25). Recently, it was
also demonstrated that caspase-1 is crucial for B. burgdorferi-
induced IL-17 responses (26). In patients diagnosed with
chronic Lyme disease, both mononuclear and T cells can be
detected in inflamed tissues, which are able to produce IL-1
and IL-17 (29, 31). It was previously described that IL-17 is
important for the development of experimental Lyme arthritis
(7). Neutralization of endogenous IL-17 in gamma interferon
(IFN-) knockout mice with Lyme arthritis resulted in a di-
minished cell influx, a reduction of swelling in the inflamed
joints, and less production of proinflammatory cytokines. Since
patients diagnosed with chronic Lyme disease often suffer from
arthritis-like symptoms, Th17 cells and/or IL-17 might be in-
volved. Not only could IL-17 be related to the development of
Lyme arthritis, but other cytokines, such as IL-6, IL-1, and
IL-23, have also been linked to the inflammatory reaction
caused by B. burgdorferi (10, 24, 32).
IL-23 is a heterodimeric member of the IL-12 family which
shares the p40 subunit but contains a specific p19 subunit
which can be recognized by the IL-23 receptor (27). Whereas
IL-6 and IL-1 are necessary for induction of Th17 cells, IL-23
is responsible for the maintenance of this T helper cell popu-
lation and production of IL-17 (1, 4, 18). In vitro studies re-
vealed that only IL-1 and IL-23 are essential to generate
Th17 cells (6). It has been demonstrated that IL-23 plays an
important role in the induction of IL-17 after cells were stim-
ulated in vitro with B. burgdorferi (19). It is also known that
transgenic mice that overexpress IL-23 are spontaneously de-
veloping autoimmune disorders. Moreover, it was shown that
IL-23 was involved in the development of murine Lyme arthri-
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tis (20). Induction of Lyme arthritis could not be observed
when B. burgdorferi-exposed animals were treated with anti-
bodies against the p19 subunit of IL-23. In addition, IL-17
levels in these animals were significantly decreased compared
to those of control animals (27). Recently it has been demon-
strated that a nonsynonymous single nucleotide polymorphism
(SNP) in the IL-23 receptor (Arg381Gln; rs11209026) is asso-
ciated with the protection from several autoimmune disorders,
including Crohn’s disease, psoriasis, and rheumatoid arthritis
(11, 16). This polymorphism is found in the cytoplasmic JAK-2
binding domain of the IL-23 receptor (IL-23R), and variations
in this area are known to interfere within the binding of IL-23
to IL-23R (13). When variations occur, it is hypothesized that
this will prevent activation of Th17 cells and thereby be pro-
tective against (chronic) disease. At this moment, IL-23 is used
as a therapeutic target in the treatment of several autoimmune
diseases, such as Crohn’s disease, psoriasis, and rheumatoid
arthritis (12).
The precise role of IL-23 in Lyme disease patients has not
been elucidated yet. We describe for the first time that IL-17
production by B. burgdorferi in humans is dependent on IL-23R
signaling and genetic variation at the level of the IL-23R gene.
In addition, we assessed whether the IL-23R Arg381Gln poly-
morphism contributes to the pathogenesis of chronic Lyme
disease.
MATERIALS AND METHODS
Bacterial cultures. The B. burgdorferi ATCC 35210 strain (B31) was cultured
at 33°C in Barbour-Stoenner-Kelley (BSK)–H medium (Sigma-Aldrich) supple-
mented with 6% rabbit serum. Spirochetes were grown to late logarithmic phase
and examined for motility by dark-field microscopy. Organisms were quantified
by fluorescence microscopy after mixing 10-l aliquots of culture material with
10 l of an acridine orange solution. Bacteria were harvested by centrifugation
of the culture at 7,000  g for 15 min and washed twice with sterile phosphate-
buffered saline (PBS; pH 7.4). Stock solutions were divided and stored at 20°C
until use. B. burgdorferi was diluted in PBS to required concentrations, 1  105
to 1  107 spirochetes/ml. Viability after freezing was confirmed using dark-field
microscopy.
Isolation of human peripheral blood mononuclear cells and in vitro cytokine
production. After obtaining informed consent, venous blood was drawn from the
cubital vein of healthy volunteers and patients into EDTA tubes of 10 ml
(Monoject). Peripheral blood mononuclear cells (PBMCs) were isolated accord-
ing to standard protocols, with minor modifications. The PBMC fraction was
obtained by density centrifugation of blood diluted 1:1 in PBS over Ficoll-Paque
(Pharmacia Biotech). Cells were washed three times in PBS and resuspended in
RPMI 1640 (Dutch modified) supplemented with 50 mg/liter gentamicin, 2 mM
L-glutamine, and 1 mM pyruvate. Cells were counted in a Coulter Counter Z
(Beckman Coulter) and adjusted to 5 106 cells/ml. Mononuclear cells (5 105)
in a 100-l volume were added to round-bottom 96-well plates (Greiner) and
incubated with either 100 l of medium (negative control) or B. burgdorferi at a
dose range between 1  104 and 1  106 spirochetes/ml. In some experiments,
PBMCs and added stimuli were coincubated with antibody (anti-hIL-23p19 an-
tibody; 5 g/ml; R&D Systems) or control antibody (normal goat IgG; 5 g/ml;
R&D Systems). After 24 h or 7 days (in the presence of 10% human pool serum),
supernatants were collected and stored at 20°C.
Study populations. (i) Healthy volunteers. Individuals used in this study were
foresters from Geldersch Landschap and Kroondomein in The Netherlands. In
this cohort (n  143 individuals), Lyme disease occurred as an occupational
disease, and these persons were selected to participate due to their relatively high
risk of infection with B. burgdorferi species. The individuals were between 23 and
73 years old, and the cohort consisted of 77% males and 23% females. Venous
blood of these individuals was drawn after informed consent was obtained.
(ii) Lyme disease patients. From September 2008 until August 2010, individ-
uals suspected of persistent Lyme disease were recruited from the outpatient
clinic of the Department of Medicine, Radboud University Nijmegen Medical
Centre. Patients were divided into three groups, based on diagnostic clinical
criteria. “Proven” Lyme disease was diagnosed when patients displayed verified
erythema migrans or ACA (B. burgdorferi PCR positive), arthritis (B. burgdorferi
PCR or culture positive in synovial fluid), or meningitis (radiculitis, pleocytosis
in liquor, or facialis paresis). At the time of inclusion, proven Lyme disease
patients also displayed clinical signs, such as persistent tiredness, musculoskeletal
complaints, paresthesia, memory and concentration disorders, or neuralgia.
Probable Lyme disease was diagnosed for patients who were clinically compa-
rable with the proven Lyme disease patients but did not display active disease
during inclusion. Patients with Lyme disease history were known to suffer (1
year ago) from clinical signs, such as EM, ACA, or arthritis, and had a positive
Western blot or enzyme-linked immunosorbent assay (ELISA), but any of the
described symptoms of disease were absent at the time of inclusion. “No Lyme”
was diagnosed when EM, ACA, arthritis, or meningitis were absent and when B.
burgdorferi Western blotting and ELISA were negative. These individuals often
displayed persistent tiredness, musculoskeletal complaints, paresthesia, or mem-
ory and concentration problems.
All patients were tested for B. burgdorferi infection by IgG and IgM ELISAs
and Western blotting. Genotyping was performed on DNA isolated from 228
patients between 16 and 80 years old. The study population was 46% male and
54% female. After informed consent was obtained, blood was drawn as described
before. All experiments were conducted according to the principles expressed in
the Declaration of Helsinki.
Isolation of genomic DNA and single nucleotide polymorphism analysis. DNA
was isolated using the Gentra Puregene blood kit (Qiagen), according to the
manufacturer’s protocol for whole blood, and dissolved in a final volume of 100
l. PCR amplification of IL-23R gene fragments bearing the polymorphism
Arg381Gln (rs11209026) was performed using a predesigned TaqMan SNP
genotyping assay (Applied Biosystems) in 25-l reaction mixtures containing 2 l
of genomic DNA as well as primers, two specific probes (with either the VIC or
FAM [6-carboxyfluorescein] label), and universal PCR 2 Master mix (Applied
Biosystems). Cycling conditions were 2 min at 50°C and 10 min at 95°C followed
by 40 cycles of 95°C for 15 s and 1 min at 60°C. Fluorescence intensities were
corrected using a postread/preread method for 1 min at 60°C before and after the
amplification. The software automatically plotted genotypes based on a two-
parameter plot with an overall success rate of95%. Intermediate samples were
excluded from the analysis.
Cytokine measurements. Concentrations of human IL-1, IL-6, IL-17, or
IFN- were determined using either specific or commercial ELISA kits (PeliKine
Compact; Sanquin Amsterdam; or R&D Systems, Minneapolis, MN), in accor-
dance with the manufacturers’ instructions. Detection limits were 40 pg/ml,
except for IFN- ELISA (12 pg/ml). IL-23 was measured using Ready-SET-Go!
ELISA from eBioscience, with a sensitivity of 15 pg/ml.
Statistical analysis. Data are expressed as means 	 standard errors of the
means (SEM) unless mentioned otherwise. Differences between experimental
groups were tested using the Mann-Whitney U test performed on GraphPad
Prism 4.0 software (GraphPad). P values of 0.05 were considered significant
and are marked with an asterisk.
RESULTS
Exposure of PBMCs to Borrelia burgdorferi induces IL-17
production. To determine the capacity of live B. burgdorferi to
induce proinflammatory cytokine production by freshly iso-
lated peripheral blood mononuclear cells (PBMCs), cells were
stimulated with spirochetes in a dose range of 1  105 to 1 
107 spirochetes/ml. After 7 days of incubation, a dose-depen-
dent production of IL-17 was detected (Fig. 1A). Since it is
known that for the development of Th17 cells and IL-17 pro-
duction IL-1, IL-6, and IL-23 are needed, we analyzed the
production of these cytokines after B. burgdorferi exposure.
IL-1 (Fig. 1B) as well as IL-23 (Fig. 1C) production could be
observed in a dose-dependent manner. In addition, B. burgdor-
feri is a potent inducer of IL-6 production (Fig. 1B). To confirm
that both IL-1 and IL-23 are important for IL-17 production
by PBMCs, we stimulated PBMCs for 7 days with IL-1 and
IL-23. Figure 1D shows that IL-1 and IL-23 induce IL-17
production. In addition to IL-17, IL-22 was also detected in
large amounts (Fig. 1D). When the medium was used as a
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background control, neither IL-17 nor IL-22 could be mea-
sured in the supernatants (data not shown).
B. burgdorferi-induced IL-17 production is dependent on
IL-23. To investigate whether IL-17 production by B. burgdor-
feri (Fig. 1A) is indeed dependent on IL-23, we neutralized
endogenous IL-23 using an antibody against IL-23p19. While
exposure of PBMCs to 1  105 live B. burgdorferi spiro-
chetes/ml induced high IL-17 production in the presence of an
isotype control antibody, almost no IL-17 production could be
detected when IL-23 was neutralized by the anti-IL-23p19 an-
tibody (Fig. 2A). To examine whether a blockade of IL-23
influences the production of cytokines other than IL-17, we
analyzed IFN-, IL-1, and IL-6. Both IL-23 and IL-12 belong
to the IL-12-family of cytokines and share a p40 subunit. Since
it is known that IL-12 is involved mainly in IFN- induction by
B. burgdorferi, we examined whether the anti-IL-23 antibody
modulates B. burgdorferi-induced IFN- production (15). No
differences in IFN- levels could be observed after B. burgdor-
feri exposure to PBMCs for 7 days in combination with the
anti-IL-23p19 antibody (Fig. 2B). In addition, no differences in
IL-1 and IL-6 production could be found when the anti-IL-
23p19 antibody was added together with live B. burgdorferi to
PBMCs (Fig. 2C and D).
PBMCs isolated from individuals bearing the IL-23R
Arg381Gln polymorphism produce less IL-17 after exposure to
B. burgdorferi. To further dissect the role of IL-23 in the pro-
duction of IL-17, PBMCs isolated from individuals carrying
different alleles of the Arg381Gln SNP of the IL-23R subunit
of the IL-23R gene were stimulated for 24 h or 7 days with B.
burgdorferi (Fig. 3). Healthy individuals heterozygous for the
IL-23R Arg381Gln polymorphism displayed a significantly
lower production of IL-17 than individuals homozygous for the
wild-type allele (Fig. 3A). Interestingly, no differences could be
observed in IL-1 or IL-6 production after 24 h of PBMC
stimulation between individuals bearing wild-type or heterozy-
gous alleles (Fig. 3B and C, respectively). As expected, no
FIG. 1. PBMCs exposed to B. burgdorferi or IL-1/IL-23 produce elevated IL-17 production. (A) A total of 5  105 peripheral blood
mononuclear cells (PBMCs) from at least 6 healthy volunteers were stimulated with different doses (ranging from 1  105 to 1  107
spirochetes/ml) of B. burgdorferi. After 7 days, IL-17 was measured in the supernatant using enzyme-linked immunosorbent assay (ELISA). Bars
represent the means 	 SEM in picograms/milliliter. *, P 
 0.05; **, P 
 0.01 using two-sided Mann-Whitney U test. (B) PBMCs were stimulated
with different concentrations of B. burgdorferi for 24 h. After stimulation, ELISA was used to measure IL-1 and IL-6 in the supernatant, and
results are represented as nanograms/milliliter in the graphs. Bars are means 	 SEM. *, P 
 0.05; **, P 
 0.01 using Mann-Whitney U test.
(C) IL-23 was measured in the supernatant after 24 h of PBMC stimulation with 1  105 to 2.5  106 spirochetes of live B. burgdorferi/ml. Bars
are means 	 standard errors of the means, and at least 6 healthy individuals were used. **, P 
 0.01; ***, P 
 0.001, Mann-Whitney U test.
(D) PBMCs from 7 healthy volunteers were stimulated for 7 days with both 10 ng/ml IL-1 and 1 ng/ml IL-23. IL-17 and IL-22 production were
measured in the supernatant using ELISA, and bars represent the means 	 SEM.
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differences in IL-23 production after B. burgdorferi stimulation
by PBMCs from both wild-type and heterozygous individuals
could be detected (Fig. 3D).
IL-23R Arg381Gln polymorphism does not influence clinical
signs of chronic Lyme disease. IL-17 is linked to the patho-
genesis of chronic inflammatory diseases, and a fundamental
role for IL-17 in chronic Lyme disease has been suggested (7).
Since we showed that the IL-23 pathway is crucial for B. burg-
dorferi-driven IL-17 production, we investigated whether indi-
viduals bearing the IL-23R Arg381Gln SNP have a different
presentation of clinical signs of chronic Lyme disease. We
analyzed a cohort of 228 individuals (foresters and Lyme pa-
tients) in total, in which several individuals were present that
expressed clinical signs of chronic Lyme disease, including
arthritis and skin disorders (ACA). We found little differences
in the incidences of EM occurrence between individuals car-
rying the wild-type or heterozygous allele of the IL-23R gene
(Table 1). Moreover, the percentages of anti-B. burgdorferi
antibodies, both IgM and IgG, were similar in both genotypes
of the IL-23 receptor. In addition, there was no decreased
expression of signs of chronic Lyme disease in individuals bear-
ing the IL-23R Arg381Gln SNP.
DISCUSSION
We assessed the role of the IL-23/IL-23R pathway for the
induction of IL-17 by B. burgdorferi spirochetes in humans.
IL-23 plays an important role in the induction and mainte-
nance of Th17 cells, but its role for B. burgdorferi-induced Th17
or IL-17 production was not yet described. We identify that
IL-23 is crucial for the IL-17 production by PBMCs after ex-
posure to B. burgdorferi spirochetes. Blockade of IL-23R using
neutralizing IL-23p19 antibodies resulted in a highly significant
suppression of IL-17 production after B. burgdorferi stimula-
tion. Of interest, we demonstrated that individuals carrying a
nonsynonymous SNP of IL-23R (Arg381Gln) showed a signif-
icantly reduced IL-17 production after cell stimulation with B.
burgdorferi. Despite the downmodulation of the IL-17 response
by the IL-23R Arg381Gln polymorphism, there was no differ-
ence in clinical or serological markers of acute Lyme disease or
FIG. 2. Borrelia-induced IL-17 is highly dependent on IL-23. (A) Peripheral blood mononuclear cells (PBMCs; 5  105/well) from 4 healthy
volunteers were stimulated for 7 days with either medium (RPMI; white bars) or 1  105 live B. burgdorferi spirochetes/ml (black bars). IL-17
production in the supernatant was measured using ELISA and is shown in picograms/milliliter. Bars represent the means 	 SEM. *, P 
 0.05,
Mann-Whitney U test. RPMI, medium; anti-IL-23, 5 g/ml specific antibody against the p19 subunit of IL-23; isotype control, goat IgG1 isotype
control, 5 g/ml. (B) IFN- production measured in supernatant after 7 days of culture of PBMCs stimulated with or without 1 105 B. burgdorferi
spirochetes/ml or in the presence or absence of 5 g/ml antibody; (C) IL-1 production in picograms/milliliter; (D) IL-6 production in
nanograms/milliliter after 7 days of stimulation. RPMI, white bars; B. burgdorferi, black bars. Bars represent the means 	 SEM.
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the occurrence of chronic symptoms of Lyme between B. burg-
dorferi-exposed individuals carrying wild-type or heterozygous
alleles. These results indicate that carrying the IL-23R SNP is
probably not essential for the development of chronic Lyme
disease.
IL-23 is known to play an important role for the induction
and maintenance of Th17 cells and the production of IL-17 (1,
4, 18). It has been demonstrated that B. burgdorferi-induced
IL-17 production in mice is dependent on IL-23 (19). Cells
from mice lacking bioactive IL-23 (p19 deficiency) were unable
to produce IL-17. Here, we showed that human PBMCs incu-
bated with a neutralizing anti-IL-23p19 antibody produced sig-
nificantly smaller amounts of IL-17. IL-23 is a member of the
IL-12 family, and IL-12 itself is a cytokine which is known to
drive IFN- production (15). Blockade of endogenous IL-12
ameliorates murine Lyme arthritis (2), and T helper 1 cell
responses (e.g., IFN-) promote the development of Lyme
arthritis. However, these studies used anti-IL-12p40 antibodies
that neutralize both IL-12 and IL-23, and it therefore cannot
be excluded that IL-23 blockade, rather than that of IL-12, led
to decreased severity of Lyme arthritis in these mice through
reduction of IL-17. We found that a specific IL-23p19 blockade
or an Arg381Gln polymorphism in IL-23R does not modulate
IFN- production by B. burgdorferi in primary cells.
B. burgdorferi spirochetes are potent inducers of IL-17 pro-
duction by human PBMCs. This is in line with previous reports
that demonstrated enhanced IL-17 production in both murine
and human T cells, after stimulation with outer surface pro-
teins isolated from B. burgdorferi spirochetes (17). Here, we
demonstrated that human PBMCs exposed to live B. burgdor-
feri spirochetes produce robust IL-17 levels, which is in line
with previous reports showing that microbial components, es-
pecially those originating from B. burgdorferi species, are po-
FIG. 3. Impaired IL-17 production in individuals bearing the IL-23R Arg381Gln SNP. (A) Peripheral blood mononuclear cells (PBMCs; 5 
105/well) from 63 healthy individuals without the Arg381Gln polymorphism (Wt, wild type [white bars]) and 18 heterozygous individuals (He,
heterozygous [black bars]) were stimulated for 7 days with either RPMI or B. burgdorferi (B.b.; 1  106 spirochetes/ml). IL-17 production in the
supernatant was measured using ELISA and is shown in picograms/milliliter. Bars represent the means	 SEM by two-sided Mann-Whitney U test.
IL-1 (B) and IL-6 (C) production in picograms/milliliter in supernatant collected after 24 h of stimulation with RPMI or B. burgdorferi. (D) IL-23
levels were measured after 24 h of stimulation of PBMCs isolated from healthy individuals without (white bars; wild type) or with the presence
of the IL-23R SNP (black bars; heterozygous).
TABLE 1. Clinical characteristics of patients with a suspicion of
chronic Lyme disease, divided on the basis of the IL-23R SNPa
Characteristic
No. of patients with: % of patients with:
Wild-type
IL-23R
Heterozygous
IL-23
Wild-type
IL-23R
Heterozygous
IL-23
Total 188 40
Female/male 100/88 22/18 53/47 55/45
Age range (mean) 16–80 (48) 17–66 (50)
Lyme history 26 5 14 13
Possible Lyme disease 134 30 71 75
Proven Lyme disease 28 5 15 12
Clinical signs or
complaint
EM 87 21 46 53
Joint 108 17 57 43
Heart 29 7 15 18
ACA 12 2 6 5
ELISA IgG positive 77 17 41 43
ELISA IgM positive 26 8 14 2
Blot IgG positive 84 21 45 53
Blot IgM positive 31 9 16 23
a Values are the numbers and percentages of patients unless otherwise noted.
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tent inducers of Th17 and/or IL-17 (9, 17, 22). Interestingly, it
was shown that IL-17 contributes to the development of mu-
rine Lyme arthritis and that blocking of the IL-17 pathway
leads to amelioration of this chronic disease (7). These data
clearly indicate that Th17 and IL-17 are valid target candidates
for therapeutic approaches in Lyme disease. This is in line with
recent reports that anti-IL-17 treatment of RA patients results
in suppression of disease activity (14).
As shown before, human PBMCs exposed to B. burgdorferi
produce proinflammatory cytokines, such as IL-1 and IL-6, in
a dose-dependent manner. These proinflammatory cytokines
are known to be necessary for an optimal Th17/IL-17 response.
Next to that, it was also demonstrated that human mononu-
clear cells (PBMCs) release IL-23 after stimulation with live B.
burgdorferi spirochetes (3). However, this group did not show a
dose-dependent induction of IL-23 production by B. burgdor-
feri species. So far, it was demonstrated only that murine bone
marrow-derived dendritic cells (BMDCs) were able to produce
IL-23 after exposure to B. burgdorferi species (19). In addition,
human neutrophils were able to induce IL-23 after stimulation
with neutrophil-activating protein A (NapA) isolated from B.
burgdorferi (9). Interestingly, when neutrophils were exposed
to B. burgdorferi-derived outer surface protein A (OspA),
which is commonly used as a B. burgdorferi antigen, IL-23
production was not observed (9). In the present study, we used
viable B. burgdorferi in order to stimulate the IL-23 production
by PBMCs.
The function of both IL-17 and IL-23 in the development of
human chronic Lyme disease is not demonstrated yet. Al-
though it has been suggested that both IL-17 and IL-23 may be
important mediators in chronic Lyme disease, this was not
confirmed in functional studies (5). In rheumatoid arthritis
(RA), it was already demonstrated that the IL-17/IL-23 axis
plays an important role and that individuals with the single
nucleotide polymorphism in IL-23R are protected against the
development of RA (16). However, the functional mechanisms
that mediate these findings were not investigated until now.
This is the first study that describes the functional conse-
quences of the IL-23R Arg381Gln SNP. It was already pro-
posed that this polymorphism might interfere with JAK-STAT
binding and therefore inhibit the activation of Th17 cells (13).
In our study, IL-17 production by PBMCs from individuals
with the IL-23R SNP is indeed significantly reduced after stim-
ulation with live B. burgdorferi spirochetes.
Despite the significant consequences of this SNP for the
release of IL-17 in vitro, individuals bearing the IL-23R
Arg381Gln polymorphism were not protected from developing
clinical signs of acute or chronic Lyme disease. The infection
rates of individuals carrying the wild type or the IL-23R SNP
were similar, indicating that the risks of symptomatic B. burg-
dorferi infection in the situation of high exposure were equal
between individuals bearing the various IL-23R genotypes. In
addition, the percentages of individuals with anti-B. burgdorferi
antibodies (IgG or IgM) were roughly the same (Table 1).
Moreover, in a cohort of patients examined for a suspicion of
chronic Lyme disease, individuals heterozygous for the IL-23R
polymorphism showed symptoms of chronic Lyme disease,
such as ACA or cardiac problems, similar to those in individ-
uals homozygous for the wild-type allele. Interestingly, the
incidence of joint problems was lower in the group heterozy-
gous for the polymorphism (43% versus 54%) than in the
group with the wild-type allele. However, this difference was
not found to be significant. It was shown before that the TLR2
Arg753Gln polymorphism may protect for the development of
late-stage Lyme disease due to a reduced signaling via TLR2/
TLR1 (28). Several reports showed that both B. burgdorferi and
Pam3Cys (TLR2 ligand originating from B. burgdorferi) are
potent inducers of IL-23. Therefore, lacking functional TLR2
could have led to reduced IL-23 production followed by lower
Th17 responses upon exposure to B. burgdorferi. This hypoth-
esis is not supported by the lack of influence of the clinical
presentation by the IL-23R polymorphisms (Table 1).
Since the IL-17 blockade was shown to be effective in sup-
pressing murine Lyme disease in IFN--deficient mice, it was
tempting to speculate about the therapeutic value of anti-IL-17
antibodies in human Lyme disease (7). Anti-IL-17 antibodies
are in development for treatment of RA patients, and the
results are promising (14). Here, we demonstrated that a poly-
morphism resulting in a nonfunctional IL-23R leads to re-
duced IL-17 production and did not influence the susceptibility
or severity of Lyme disease in humans. While this may be an
argument against therapeutic usage of anti-IL-17 antibodies in
chronic Lyme disease, one important aspect may be repre-
sented by the degree of IL-17 blockade attained by therapeutic
antibodies. This may be much higher than that of the IL-23R
polymorphism.
In conclusion, the contribution of the IL-23/IL-17 axis to the
development of the chronic stages of Lyme disease is limited,
and other pathological pathways need to be explored in the
future. Apart from IL-17, B. burgdorferi spirochetes are potent
inducers of IL-1, which is a classic proinflammatory cytokine
(5). The latter cytokine is linked to the development of several
autoinflammatory diseases, such as gout and fever syndromes,
and may represent a more attractive therapeutic target in
chronic Lyme disease.
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